LOCAMETZ (Gallium Ga-68 Gozetotide) Patent Expiration, LOE Window & CMS Spending

LOCAMETZ (Gallium Ga-68 Gozetotide) by Novartis: FDA Orange Book core substance LOE 2028-08-15 (last listed 2036-03-09), 0 AB generics, $0 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNovartis
FDA Application & PathwayN215841 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2028-08-15
Last Listed Patent or Exclusivity Date2036-03-09
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.